Context: Male ageing is associated with lower circulating testosterone (T) and increased incidence of cardiovascular disease (CVD). Whether physical activity (PA) interacts with hormones to modify CVD risk is unclear.
| Survey measurement methods
Methods used in the 1994/95 Busselton Health Survey have previously been described. 19 All men completed a comprehensive health and lifestyle questionnaire and underwent a physical assessment that included anthropometry (height, weight, waist circumference via standardized protocols) and blood pressure (systolic and diastolic via mercury sphygmomanometer after 5 minutes of seated rest) and a fasting blood sample. Smoking, diabetes, medication use and hours of PA for exercise/leisure, at home and at work per usual week were obtained by questionnaire. 20 Participants were asked how many hours were spent engaging in moderate or vigorous activities in each of the three environments with examples given for each. For each physical activity setting, we calculated (hours per week of moderate-intensity activities)+2×(hours per week of vigorous-intensity activity). Body mass index (BMI) was calculated as weight (kg) divided by square of height (m).
| Laboratory assays
Serum cholesterol, high-density lipoprotein (HDL) and triglycerides (TG) were assayed using a Hitachi 747 analyser (Roche Diagnostics, Castle Hill, NSW, Australia) and glucose using a hexokinase assay at the time of survey. Serum was stored at −70°C, and serum T, DHT and E2 were measured from 200 μL samples in 2013 using a single liquid chromatography-tandem mass spectrometry (LC-MS) run without derivatization using atmospheric pressure photoionization for positive mode for androgens and negative mode for oestrogens, as previously described. 9, 21 Between-run imprecision for T was 8.6%
at 5.3 nmol/L and 7.9% at 26.9 nmol/L. For DHT, between-run imprecision was 11.3% at 1.3 nmol/L and 9.1% at 5.3 nmol/L. For E2, between-run imprecision was 14.5% at 73 pmol/L and 9.9% at 279 pmol/L. 9 LH was assayed using immunoassay (Abbott Architect, Abbott Diagnostics, Australia) with between-run imprecision of 5.6% 
| Definition of metabolic syndrome and prevalent cardiovascular disease
The metabolic syndrome score was defined using five risk components 
| Ascertainment of fatal and nonfatal cardiovascular events during follow-up
Follow-up for hospital admissions and deaths was available until mid-2014, amounting to 20 years of follow-up. Outcome events were ascertained from hospital admissions and death records. Hospital admission codes used the ICD-9/ICD-9-CM system up to mid-1999 and ICD-10-AM thereafter. Deaths from CVD were ascertained based on deaths with underlying cause of death coded as diseases of the circulatory system (ICD-9 390-459; ICD-10 I00-99, G45). Nonfatal CVD events were defined as a hospital admission with a principal diagnosis of coronary heart disease (ICD-9 410-414; ICD-10 I20-25), stroke (ICD-9 430-437;
ICD-10 I60-68, G45), congestive heart failure (ICD-9 428; ICD-10 I50)
or peripheral arterial disease (ICD-9 440-448; ICD-10 I70-79).
| Statistical analysis
Characteristics of the survey sample are expressed as mean (SD) and median (interquartile range) for continuous data, and N (%) for categorical data. Men were divided into four groups: (1) high PA and high hormone (H/H), (2) low PA and high hormone (L/H), (3) high PA and low hormone (H/L) and (4) low PA and low hormone (L/L), based on using median splits to determine high/low. For frequencies of the four groups, see Table S1 . In the cross-sectional analyses, linear regression was used to compare mean BMI and waist circumference (after adjustment for age) across the four groups. Logistic regression was used to compare the prevalence of metabolic syndrome (after adjustment for age) across the four groups. In the longitudinal follow-up analysis, Cox proportional hazards regression analysis was used to compare risk of fatal and nonfatal CVD events (after adjustment for age, prevalent CVD, smoking, waist circumference, cholesterol, HDL, lipids medication, diabetes, SBP and hypertension medication) across the four groups. PA*hormone interaction analyses were conducted using PA and hormones as continuous variables.
| RESULTS

| Baseline characteristics of study population
After restricting the cohort to men aged 20-79 years and excluding men who were taking androgens, anti-androgens, or had a history of orchidectomy or prostate cancer, or with missing PA or hormone variables, 1649 men were included in the analysis. Baseline demographic, physical and biochemical data are shown in Table 1 .
| Associations of physical activity and sex hormones with BMI
There was an inverse association of higher PA and higher T with lower BMI in the age-adjusted model ( 
| Associations of physical activity and sex hormones with waist circumference
There was an inverse association of higher PA and higher T with waist circumference in the age-adjusted model ( were present for work PA*DHT (P=.006) and total PA*DHT (P=.001).
There was a greater difference in waist circumference between men with low DHT vs men with high DHT irrespective of PA. For higher work and total PA, waist circumference was significantly lower in men with low DHT but not in men with high DHT (see Table S7 ). Men with higher leisure, home or total PA and higher E2 had significantly smaller waist circumferences (eg leisure H/H 91.6, P<.001 vs L/L 93.9 cm).
There were no PA interactions for T (all P≥.26) or E2 (all P≥.09).
| Associations of physical activity and sex hormones with metabolic syndrome
For all settings of PA, men with higher PA and higher T had lowest (ageadjusted) odds of metabolic syndrome ( (Tables S2-S4 ).
| Associations of physical activity and sex hormones with incident CVD events
In the fully adjusted model, there were no differences in the hazard ratio for CVD events for PA and hormones and no PA*hormone interactions (Table 5 ).
| Associations of physical activity and sex hormones with CVD deaths
In the fully adjusted model, men with higher leisure, work or total PA 
| Longitudinal analyses of PA and cFT and PA and SHBG
For the outcome of CVD events and CVD deaths, there were no consistent associations observed (Tables S5 and S6 ). Men with high work PA and high cFT had a lower hazard ratio for CVD death, but this was not seen for men with high leisure, home or total PA and high cFT (Table S6) . Men with high work or total PA and low SHBG had a lower hazard ratio for CVD death, but this was not seen for men with high leisure or home PA and low SHBG (Table S6 ).
| DISCUSSION
Higher PA and higher T or DHT were associated with lower BMI, waist circumference and odds of metabolic syndrome. There was an interaction between PA and DHT, with less difference in odds We found that men with higher PA levels and higher levels of T had the lowest BMI, waist circumference and risk of metabolic system. Interestingly, this did not translate to any reduction in risk of CVD events or CVD mortality. Several epidemiological studies have reported associations of low T with poorer CVD-related outcomes in men, 10, 24 while others have reported negative or neutral results. [30] [31] [32] Low T concentrations have been associated with increased risk of mortality in the European Male Ageing Study. 27 However, in older men, an optimal or mid-range T is the best predictor of longevity. 11 In this cohort of men, T appears to have less predictive utility for longitudinal CVD-related outcomes compared with DHT.
Men with higher PA and higher DHT had a lower BMI, waist circumference and risk of metabolic syndrome than men who had lower PA levels and/or lower DHT levels. There was an interaction between PA and DHT with respect to waist circumference. As a group, men with high DHT had lower waist circumference compared to men with low DHT, and the relationship of higher PA with lower waist circumference was strong (and significant) in men with low DHT and weak (and nonsignificant) in men with high DHT. Men with higher leisure, work or total PA and higher DHT also had the lowest risk of CVD mortality. There were no interactions between PA and DHT for this longitudinal outcome. This is concordant with our previous finding that older men with higher DHT have a lower mortality from ischaemic heart disease. 11 Furthermore, in the Cardiovascular Health Study there was a curvilinear association between DHT and CVD but an inverse association with all-cause mortality. 28 Those studies did not examine whether PA and T or DHT might interact to influence outcomes. Our results from men across a range of ages extend these observations demonstrating additive or independent associations of higher PA and higher DHT with lower CVD mortality, highlighting the value of DHT as an informative biomarker.
Men who had higher leisure PA levels had a significantly lower BMI and waist circumference than men who exercised less, independent of E2 levels. However, men with higher (leisure, home, work or total) PA levels and higher E2 had significantly reduced risk of metabolic syndrome compared to men with high E2 and low PA.
The difference associated with PA was not as apparent in men with low E2. Low leisure, home or work PA coupled with a high E2 level was predictive of increased CVD mortality. Previous epidemiological studies have not associated E2 with mortality from ischaemic heart disease or all-cause mortality. 11, 26 However, other studies have reported an inverse association with E2 and CVD mortality 29 and allcause mortality. 24, 30 Results from the present study indicate that in men with higher E2 levels, having higher rather than lower PA levels is associated with more favourable cross-sectional and longitudinal outcomes.
We acknowledge several limitations of the present study. As this was an observational study, it precludes the ability to infer causality.
Physical activity data were obtained via questionnaires susceptible to recall bias. Both PA and hormones were assessed at baseline, and we did not include serial measures of these variables over time. We dichotomized variables for ease of presentation and interpretation of results.
However, we also analysed interactions with PA and hormones as continuous variables. While there is the possibility of false-positive findings occurring by chance due to multiple comparisons, it is reassuring that we have found consistently significant results in specific PA and hormone groups across the different categories of PA. As men in the analysis had attended previous surveys, a "healthy survivor" effect may be present. Lastly, the BHS men are predominantly Anglo-Celtic, so results may not apply to men from other ethnic backgrounds or to women.
The androgen receptor (AR) gene contains a CAG repeat sequence, and receptors with longer CAG repeat sequences exhibit impaired transcriptional activity. 33 In men with type 2 diabetes, the AR CAG repeat was positively associated with waist circumference and BMI independently of testosterone and oestradiol concentrations. 34 Conversely in a different study, men with shorter CAG repeats had higher systolic blood pressure and lower HDL cholesterol. 35 As we did not measure 18 where findings were generally consistent with previous studies indicating that T+PA improved body composition measures more so than either intervention alone. However, the aforementioned studies were designed to detect differences in body composition and muscle strength and performance, rather than cardiometabolic outcomes. Of note, a recent meta-analysis limited to rigorous double-blind placebocontrolled RCTs of testosterone in men with metabolic syndrome or diabetes showed a marginal improvement in indices of insulin sensitivity, but no evidence of better glycaemic control in men with relatively wellcontrolled diabetes, or improvement in the Aging Male Symptom score.
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Our findings are consistent with independent and additive associations of PA and T on indices of body composition, with no evidence of interaction to suggest that one might modify the association of the other. Men with higher PA and higher DHT had lower BMI, waist circumference and metabolic syndrome, with an interaction between PA and DHT on waist circumference. Unlike the longitudinal analyses of PA and T, which showed no associations with CVD mortality, men with higher PA and DHT levels had lower risk of CVD mortality. Of note, men with high E2 and high PA were less likely to have metabolic syndrome, but those with high E2 and low PA had increased risk of CVD death. Overall, our results suggest that high PA and androgens, particularly DHT, predict more favourable outcomes. Conversely, high E2 and low PA predict less favourable outcomes. Key questions remain as to the direction of causation, and whether manipulation of both PA and hormone levels could modify cardiovascular risk.
A 2×2 factorial RCT in men with low-normal baseline T would be needed to clarify whether an exercise intervention combined with T would reduce cardiovascular and mortality risk more than either alone, or neither. Analyses of on-treatment concentrations of the T metabolites, DHT and E2, in relation to the study outcomes would also provide greater understanding of the potential contribution of each hormone in the presence of PA. However, benefits of such interventions need to be weighed carefully against the potential risks in the light of a recent systematic review demonstrating a possible increased risk of CV events during the first 12 months for men ≥65 years receiving T supplementation.
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| CONCLUSIONS
The most favourable combination of PA and hormone variables appears to be higher T and DHT with greater PA. Conversely, men with higher E2 levels have less favourable outcomes in the presence of lower PA. Causality remains to be proven by appropriately designed randomized controlled trials.
